{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:47:33Z","timestamp":1785898053406,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["24HA2007"],"award-info":[{"award-number":["24HA2007"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jval.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:04:41Z","timestamp":1770077081000},"page":"1192-1200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic Impact of Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination and Nirsevimab Prophylaxis on Respiratory-Syncytial-Virus-Associated Disease Among Japanese Infants"],"prefix":"10.1016","volume":"29","author":[{"given":"Shu-ling","family":"Hoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xerxes","family":"Seposo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10340","key":"10.1016\/j.jval.2026.01.010_bib2","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"Suppl B","key":"10.1016\/j.jval.2026.01.010_bib3","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0954-6111(02)90066-1","article-title":"Respiratory syncytial virus prophylaxis--the story so far","volume":"96","author":"Simoes","year":"2002","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.jval.2026.01.010_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.jval.2026.01.010_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pedneo.2023.04.015","article-title":"Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6\/7 weeks\u2019 gestation in the United States","volume":"65","author":"Yu","year":"2024","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.jval.2026.01.010_bib8","author":"Newsroom"},{"issue":"1","key":"10.1016\/j.jval.2026.01.010_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/ped.14957","article-title":"Epidemiology of respiratory syncytial virus in Japan: a nationwide claims database analysis","volume":"64","author":"Kobayashi","year":"2022","journal-title":"Pediatr Int"},{"issue":"1","key":"10.1016\/j.jval.2026.01.010_bib11","first-page":"15","article-title":"Contribution of palivizumab in Japan about 2 decades after introduction","volume":"45","author":"Nomoto","year":"2024","journal-title":"Ther Res"},{"issue":"6","key":"10.1016\/j.jval.2026.01.010_bib12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40121-024-00975-6","article-title":"Cost-effectiveness analysis of maternal immunization with RSVpreF vaccine for the prevention of respiratory syncytial virus among infants in Spain","volume":"13","author":"\u00c1lvarez Aldean","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jval.2026.01.010_bib13","article-title":"Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination","volume":"38","author":"Hodgson","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"10","key":"10.1016\/j.jval.2026.01.010_bib14","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s40121-024-01037-7","article-title":"Disease burden associated with all infants in their first RSV season in the UK: a static model of universal immunization with nirsevimab against RSV-related outcomes","volume":"13","author":"Kieffer","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"21","key":"10.1016\/j.jval.2026.01.010_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126164","article-title":"Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants","volume":"42","author":"Gebretekle","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2026.01.010_bib16","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: a simulation study","volume":"28","author":"Shoukat","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"9","key":"10.1016\/j.jval.2026.01.010_bib17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.vaccine.2023.01.058","article-title":"Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: evaluation for six European countries","volume":"41","author":"Getaneh","year":"2023","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jval.2026.01.010_bib18","article-title":"Cost-effectiveness of nirsevimab for respiratory syncytial virus in infants and young children","volume":"154","author":"Hutton","year":"2024","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.jval.2026.01.010_bib19","article-title":"Cost-effectiveness of maternal vaccination to prevent respiratory syncytial virus illness","volume":"154","author":"Hutton","year":"2024","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.jval.2026.01.010_bib20","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40121-024-01000-6","article-title":"Cost-effectiveness analysis of maternal respiratory syncytial virus vaccine in protecting infants from RSV infection in Japan","volume":"13","author":"Ishiwada","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.jval.2026.01.010_bib21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40121-025-01134-1","article-title":"Cost-Effectiveness and Public Health Impact of Universal prophylaxis with Nirsevimab against respiratory syncytial virus (RSV) Infections in all Infants in Japan","volume":"14","author":"Noto","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jval.2026.01.010_bib22","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268821000340","article-title":"Seasonal shift in epidemics of respiratory syncytial virus infection in Japan","volume":"149","author":"Miyama","year":"2021","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jval.2026.01.010_bib23","unstructured":"Status of RS Virus Infections in Japan From 2018 to 2021 Based on the Survey of Infectious Disease Outbreak Trends. [Kansensyou hase doukou tyousa kara miru 2018nen\u223c2021nen no wagakuni no RS wirus kansennsyou no joukyou]. [In Japanese]. Tokyo: Centre for Epidemiology of Infectious Diseases, National Institute of Infectious Diseases; 2022. Accessed April 8, 2024."},{"key":"10.1016\/j.jval.2026.01.010_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880368","article-title":"RSV prevention in all infants: which is the most preferable strategy?","volume":"13","author":"Esposito","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jval.2026.01.010_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (maternal immunization study for safety and efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial","volume":"145","author":"Sim\u00f5es","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.jval.2026.01.010_bib28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jval.2026.01.010_bib29","author":"Pedro"},{"issue":"5","key":"10.1016\/j.jval.2026.01.010_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1447-0756.2011.01812.x","article-title":"Review of the pandemic (H1N1) 2009 among pregnant Japanese women","volume":"38","author":"Nakai","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.jval.2026.01.010_bib31","first-page":"671","article-title":"Results of the 2010 infant physical growth survey [Heisei 22 nen nyuyouji shintai hatsuiku chousa kekka ni tuite]","volume":"5","author":"Kato","year":"2024","journal-title":"ShouNi HoKen KenKyu"},{"key":"10.1016\/j.jval.2026.01.010_bib32","series-title":"The 22nd Life Tables","year":"2012"},{"issue":"Suppl 60","key":"10.1016\/j.jval.2026.01.010_bib34","article-title":"Evaluation on RSV disease burden in Japanese Children using a nationwide claims database","volume":"48","author":"Goto","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jval.2026.01.010_bib35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jiac.2021.11.007","article-title":"Disease burden of respiratory syncytial virus infection in the pediatric population in Japan","volume":"28","author":"Nagasawa","year":"2022","journal-title":"J Infect Chemother"},{"issue":"3","key":"10.1016\/j.jval.2026.01.010_bib36","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/JCM.02132-10","article-title":"High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan","volume":"49","author":"Yamaguchi","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"16","key":"10.1016\/j.jval.2026.01.010_bib37","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2026.01.010_bib38","article-title":"Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case-control study","volume":"44","author":"Lassoued","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jval.2026.01.010_bib39","author":"Roy"},{"issue":"10","key":"10.1016\/j.jval.2026.01.010_bib40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2217\/fvl-2023-0069","article-title":"Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults","volume":"18","author":"Igarashi","year":"2023","journal-title":"Future Virol"},{"issue":"1","key":"10.1016\/j.jval.2026.01.010_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","article-title":"Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system","volume":"23","author":"Hasegawa","year":"2020","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2026.01.010_bib42","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jiac.2022.03.001","article-title":"Epidemiological and clinical characteristics of infections with seasonal human coronavirus and respiratory syncytial virus in hospitalized children immediately before the coronavirus disease 2019 pandemic","volume":"28","author":"Kume","year":"2022","journal-title":"J Infect Chemother"},{"issue":"41","key":"10.1016\/j.jval.2026.01.010_bib43","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:06:16Z","timestamp":1785895576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1098301526000355"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.01.010","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Impact of Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination and Nirsevimab Prophylaxis on Respiratory-Syncytial-Virus-Associated Disease Among Japanese Infants","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}